Navigation Links
Highmark Presents Work on MRSA Prevention at National Health Care Quality Conference
Date:12/11/2007

QualityBLUE program works with hospitals to help reduce spread of MRSA

PITTSBURGH, Dec. 11 /PRNewswire/ -- At a national forum on quality in health care, Highmark officials presented information on one aspect of their pay-for-performance program designed to deal with Methicillin Resistant Staphylococcus Aureus (MRSA). Highmark's program, called QualityBLUE, has been extremely successful for hospitals in western Pennsylvania in identifying patients that have been infected with the disease.

"By identifying patients who are carriers of MRSA earlier than in the past, hospitals are reducing the spread of the disease and reducing mortality, decreasing length of stay and use of antibiotics, and ultimately having significantly improved outcomes for patients," said Deborah Donovan, director, Provider Quality Performance Management at Highmark. "Highmark is working collaboratively with 30 hospitals in Pennsylvania. It is in great part because of this cooperation that the program has been so successful."

The poster presentation was made today at the 19th Annual National Forum on Quality Improvement for Health Care in Orlando, Fla. and sponsored by the Institute for Healthcare Improvement (IHI). In December 2006, the IHI added the reduction of MRSA infections to its new 5 Million Lives campaign. Participating hospitals submit such data as the percentage of patients who were tested for MRSA on admission and compliance with prevention techniques.

Highmark's pay-for-performance program began targeting MRSA testing and prevention initiatives in July 2005. "We have made it easier for participating hospitals to work with IHI and Highmark," said Donovan.

Results from Highmark's fiscal year 2007 review show that during the past year, 8.4 percent of patients admitted to hospitals' high-risk areas such as the intensive care unit were identified as carriers of MRSA. With the thorough screening program, the spread of MRSA has been reduced. Measures that participating hospitals use to reduce the spread once the patient is identified as a carrier include placing the patient in isolation, using dedicated equipment, and strict adherence to appropriate hand hygiene.

Donovan says the QualityBLUE program has expanded for fiscal year 2008 for the participating hospitals in western and central Pennsylvania. Each hospital identified three units within its facility for intense activities designed to reduce MRSA transmission.

Highmark Inc.

As one of the leading health insurers in Pennsylvania, Highmark Inc.'s mission is to provide access to affordable, quality health care enabling individuals to live longer, healthier lives. Based in Pittsburgh, Highmark serves 4.6 million people through the company's health care benefits business. Highmark contributes millions of dollars to help keep quality health care programs affordable and to support community-based programs that work to improve people's health. Highmark exerts an enormous economic impact throughout Pennsylvania. A recent study states that Highmark's positive impact exceeded $2.5 billion. The company provides the resources to give its members a greater hand in their health.

Highmark Inc. is an independent licensee of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. For more information, visit http://www.highmark.com.


'/>"/>
SOURCE Highmark Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Dublin ... the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global market ... its applications in various applications. The report deals with ... main industries: pharmaceutical and biotechnology, food and beverage, and ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
Breaking Medicine Technology:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):